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Introduction
Genomic alterations in the Ewing sarcoma family of
tumors (EFT) were discovered . 30 years ago with
the identification of the reciprocal translocation, t(11;
22)(q24;q12), otherwise known as EWS-FL1.1,2 In the
time since, multiple other fusion partners with EWS
have been identified that fit a similar Ewing sarcoma
phenotype.3,4 When EWS fusions are not identified,
tumors with histologic features of Ewing sarcoma have
been labeled as primitive neuroectodermal tumors. In
2012, Pierron et al5 identified a subset of Ewing-like
tumors harboring paracentric inversion on the short
arm of chromosome X, resulting in the fusion of the
BCOR and CCNB3 genes.5 Since that discovery,
several small case series have further elucidated the
clinical, morphologic, and genomic differences that
make this diagnosis distinct from other round cell
sarcomas, most notably Ewing sarcoma.6-8
Though distinct from Ewing sarcoma, most BCOR-
CCNB3–fused sarcomas (BCS) are treated with upfront
compressed chemotherapy with vincristine, doxoru-
bicin, cyclophosphamide, ifosfamide, and etopo-
side plus local control with surgery and/or radiation.
BCS shares similar event-free and overall survival rates
with the standard EWS-FLI1–fused Ewing sarcoma
using this treatment strategy.6-8 Despite the growing
knowledge base related to BCS, little is known about
potential drug targets related to this disease entity,
especially with regard to treatment of disease re-
currence. We highlight the treatment of a young pa-
tient who had multiply-relapsed disease with the
US Food and Drug Administration–approved cyclin-
dependent kinase 4/6 (CDK4/6) inhibitor palbociclib;
the tumor harbored a BCOR-CCNB3 fusion and a
germline variant in CDKN2B, and treatment resulted
in a complete response and no evidence of disease
25 months into therapy.
Case History
Our male patient initially presented in 2010 at 1 year of
age with a fixedmass on his back. Magnetic resonance
imaging of the pelvis showed a large infiltrating
presacral mass measuring 14 × 7.4 × 10.4 cm
extending into the lower spinal canal, eroding the
posterior right sacrum, and exerting a mass effect on
both the rectum and bladder. A core needle biopsy
was performed, which revealed a malignant, small,
round, blue cell tumor along with small amounts of
benign fibrofatty tissue and skeletal muscle. Tumor
nuclei were round to oval with a fine-grained chromatin
pattern and occasional small nucleoli or chromocen-
ters. Immunohistochemical stains were positive for
CD99, Fli1, and vimentin and were negative for NSE,
synaptophysin, MYF4, GAF, CD45RB, and TdT—
consistent with a primitive neuroectodermal tumor. No
polymerase chain reaction–base fusion analysis
or breakapart fluorescence in situ hybridization probe
for EWSR1 was performed at the time. Three gener-
ations of family history were negative for malignancies
on either side of the family, including melanoma or
pancreatic cancer. A staging computed tomography
scan of the chest and a bone scan showed no evi-
dence of metastatic disease. The patient started
chemotherapy per Children’s Oncology Group protocol
AEWS0031, regimen B2, with ifosfamide, etoposide,
vincristine, doxorubicin, and cyclophosphamide.
Gross total resection was not feasible at the time per
neurosurgery, and the patient received 57.6 Gy of
proton beam radiation in October 2010. The patient
remained in remission for . 2 years but then devel-
oped multiple local recurrences without metastases
from 2013 to 2017 and underwent numerous sur-
geries, along with multiple different early-phase
Children’s Oncology Group therapeutic studies, as
outlined in the timeline in Figure 1A. After the most
recent recurrence in October 2016, the patient was
referred to our Pediatric Cancer Precision Genomics
Program. Because of the findings outlined here in the
Results, we chose to start palbociclib in February
2017. This patient has no evidence of disease on
imaging 25 months into therapy (Fig 1B) and has had




















Whole-genome sequencing, RNA sequencing (RNA-Seq)
analysis, germline exome sequencing, and protein evalu-
ation were performed at the Clinical Laboratory Improvement
Amendment (CLIA)–approved laboratory, NantOmics (Cul-
ver City, CA). Somatic DNA changes were determined by
comparing the whole-genome DNA sequence from the
tumor with the patient’s germline sequence at 33X cov-
erage. The mutational burden of the tumor was relatively
low at 75,046 somatic mutations, with only 88 somatic
mutations mapping to protein coding regions (Circos plot in
Fig 2A). The tumor harbored an in-frame fusion of the
second base in the last codon of BCOR exon 15 (chrX:
39,911,366) and the first base of CCNB3 exon 5 (chrX:
50,051,505) (Fig 2B). Additionally, an undescribed
somatic mutation in the SMO gene (SMO N476S) was
identified in the tumor, and germline sequencing revealed
a CDKN2B N41D missense variant, which was heterozy-
gous in both the germline and tumor genomes of this
patient. RNA-Seq was also performed by NantOmics, and
mRNA transcripts were ranked by abundance, which
could be associated with increased pathway activity and
sensitivity to a targeted drug. Overexpression of relevant
tumor-promoting pathways is displayed in Table 1 and
Figure 2C.
Discussion
Germline and somatic whole-genome DNA sequencing
combined with RNA sequencing was used with the goal of
developing a treatment plan, and it surprisingly provided
our team with a more defined diagnosis of a recurrent BCS.
The specific intrachromosomal fusion between BCOR and
CCNB3 in our patient’s tumor is identical to previously
described cases.5,6 The BCOR gene itself can fuse to
a number of 3′ partner genes in round cell sarcomas or
additionally have internal tandem duplications, which have
been reported to drive similar transcriptional patterns in
a variety of sarcomas.5,8,9 Similar to previous studies of
mRNA transcripts in BCS,5,8,9 both BCOR and CCNB3
transcripts were highly overexpressed in our patient’s tu-
mor, as were theHOX-A, -B, and -C gene clusters (Table 2).
Furthermore, analysis of our patient’s tumor (Table 1)






























































Before palbociclib 2 cycles of palbociclib 3 cycles of palbociclib 2 years of palbociclib
NED
Initial diagnosis 
FIG 1. Patient timeline and response imaging. (A) The timeline of treatments and disease recurrences and progression in our patient. Red circles represent
time of recurrence or progression. Hash marks represent prolonged period of time progressed through therapy (not to scale of remaining timeline). Patient
is still continuing with palbociclib therapy after the most recent scans in March 2019. (B) Patient imaging displayed with initial diagnostic magnetic
resonance imaging from 2010; subsequent relapse scans were done via computed tomography imaging. Red lines outline tumor boundaries. There was
concern for progression after 2 cycles of palbociclib, but there was a 2-month lag between the “before palbociclib” scan and actually starting drug, so
interval progression likely occurred in this timeframe. No new baseline scan was performed on the day palbociclib started. Each cycle of palbociclib was 28
days. NED, no evidence of disease.
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the Riggi_Ewing_sarcoma_progenitor signature, which can
be used to distinguish between BCS and EWS.5,10 Most
notable for this patient was the observation that multiple
genes in the CDK4/6–RB pathway (Table 1; Fig 2C) were
overexpressed, which made palbociclib, which has known
pediatric dosing information, an attractive drug to use in
this case.
Curiously, our patient was diagnosed at a very young age
compared with the literature on BCS. In the several case
series describing BCS, the median age of diagnosis is in the
teenage years, with the youngest patient recorded at age
2.5-8,11 Again, because of the age of presentation, one could
be concerned about an inherited cancer syndrome. Alfaro-
Cervello et al12 published a case report of a congenital
undifferentiated sarcoma with BCOR-CCNB3 fusion pos-
sibly similar to our patient case. This congenital tumor also
harbored a SMARCB1/INI1 gene deletion common to
malignant rhabdoid tumor, epithelioid sarcomas, and ep-
ithelioid malignant peripheral nerve sheath tumor that also,
when found germline, is known to cause rhabdoid tumor
predisposition syndrome.12-16 In the case reported by
Alfaro-Cervello et al,12 INI1 germline analysis was not
performed. Our patient’s tumor had functionally intact INI1,
which precludes an effective comparison. Our patient
also harbored a germline heterozygous missense variant,
CDKN2B N41D. It is unclear what role this germline
CDKN2B N41D variant could play in sarcomagenesis, as
cancer risks associated with CDKN2A/B gene variants in-
clude melanoma, pancreatic cancer, and astrocytomas.17,18
There is a recent short report from Jouenne et al19 that found
an increased risk of soft tissue sarcoma development with
germline loss of CDKN2A, though no data exist confirming
this risk with CDKN2B variants. Additionally, little is known
about this actual variant in CDKN2B. Sunita et al20 showed
that the specific CDKN2B N41D variant, which encodes
p15(INK4B), is unable to bind to the CDK6 protein, leading
to loss of function of CDKN2B, which could lead to dysre-
gulated control of S-phase entry. Though this variant’s
contribution to tumorigenesis is intriguing, CKDN2B was
normally expressed in our patient’s tumor, and there are no
data suggesting that this impaired binding to CDK6 leads to
mRNA overexpression along multiple levels of the CDK4/6
pathway.
Despite discovering alterations of several key regulators of
the CDK4/6 pathway in this tumor, none have been proven
to serve as clinical biomarker for sensitivity to CDK4/6
inhibitors.21 In a preclinical Ewing sarcoma orthotopic xe-
nograft model with CDKN2A deletion, palbociclib was able
to greatly suppress growth despite doxorubicin resistance
of this model.22 In other sarcoma subtypes, palbociclib
reduced tumor burden in murine preclinical models.23-25
Clinically, there is phase II evidence of palbociclib’s efficacy
in adults with liposarcoma26,27 and leiomyosarcoma.28
Despite growing evidence in these sarcomas, there are
no published data testing CDK4/6 inhibitors in BCS. Ad-
ditionally, though phase I/II trials are underway, the only
published response data for palbociclib in pediatrics is
a case report of growing teratoma syndrome,29 thus making
our use of this drug in a child novel.
To summarize, 3 independent observations supported
consideration of therapeutic inhibition of the CDK4/6-RB1
pathway for this patient: (1) the presence of the BCOR-
CCNB3 gene fusion believed to drive entry into the cell
cycle, (2) direct detection of an active CDK4/6-RB1
TABLE 1. Overexpression of Relevant Tumor-Promoting Pathways
Gene TPM Status Gene Function
CCND1 935 Overexpressed Activating cyclin for CDK4 and CDK6
CCND2 69 Overexpressed Activating cyclin for CDK4 and CDK6
CDK4 168 Overexpressed RB1 protein kinase
E2F1 47 Overexpressed RB1-regulated transcription factor
E2F2 24 Overexpressed RB1-regulated transcription factor
E2F3 21 Overexpressed RB1-regulated transcription factor
CDC25A 11 Overexpressed E2F-regulated gene
CDC25C 7 Overexpressed E2F-regulated gene
CDC25B 96 Overexpressed E2F-regulated gene
TOP2A 162 Overexpressed E2F-regulated gene
BUB1 35 Overexpressed E2F-regulated gene
BUB1B 35 Overexpressed E2F-regulated gene
NOTE. RNA sequencing (RNA-Seq) data highlights the transcripts of the CDK4/6
pathway that were overexpressed in our patient’s tumor. processed by RNA-seq by
Expectation-Maximization (RSEM) to estimate TPMs. Gene-level TPMs were used
to determine if the gene was overexpressed using the upper 5th percentiles of per-
gene RSEM TPM values for a collection of RNA-Seq datasets from The Cancer
Genome Atlas normal samples. The expression status for a gene was classified as
overexpressed if its TPM exceeded the gene’s upper 5th percentile.30
Abbreviations: CDK, cyclin-dependent kinase; E2F, E2 transcription factor; RB1,
retinoblastoma gene; TPMs, transcripts per million.
FIG 2. Transcriptome analysis reveals activation of the cyclin-dependent kinase 4/6 (CDK4/6)-RB pathway. (A)
Circos plot of patient’s tumor genome. (B) Identification of BCOR-CCNB3 fusion. This graphic illustrates the
fusion of BCOR exon 15 to CCNB3 exon 5. With the exception of the destruction box in CCNB3, all functional
domains from each encoded protein remain intact in the BCOR-CCNB3 fusion protein. (C) The CDK4/6 pathway
is a gene regulatory program controlled by multiple tiers of protein kinases and transcriptional regulators.
Increases in cyclin-D or CDK4 or 6 protein can lead to phosphorylation of the RB1-E2F tumor suppressor
complex. Upon phosphorylation of RB1, the E2F1-3 transcription factors are released from the complex and are
able to bind to the promoters of target genes, driving activation of transcription. These target genes include
E2F1-3 themselves, the CDC25 genes, TOP2A, BUB1, and BUB1B. WT, wild type.
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pathway, and (3) the presence of a germline CDKN2B
variant. Using this information, our Precision Genomics team
chose to place our patient with multiply-relapsed disease on
palbociclib; the patient has now benefited from. 2 years of
disease remission. The sustained complete response with
palbociclib in our patient makes this case a novel and in-
teresting application of palbociclib use and argues for ad-
ditional research using CDK4/6 inhibitors in BCS.
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TABLE 2. Comparison of Patient Transcriptome With Published BCS Reference Publications
Gene BCS Signature Reference Patient With BCS Watson et al9 Reference Pierron et al5 Reference
HOX-A family Watson,9 Pierron5 Overexpressed Overexpressed Overexpressed
HOX-B family Watson,9 Pierron5 Overexpressed Overexpressed Overexpressed
HOX-C family Watson,9 Pierron5 Overexpressed Overexpressed Overexpressed
HOX-D family Watson,9 Pierron5 Overexpressed Overexpressed Overexpressed
HMX1 Watson9 Overexpressed Overexpressed Underexpressed
PITX1 Watson9 Normal Overexpressed Overexpressed
ALX4 Watson9 Overexpressed Overexpressed ND
DLX1 Watson9 Overexpressed Overexpressed Overexpressed
RET Watson9 Normal Overexpressed Normal
FGFR2 Watson9 Overexpressed Overexpressed Overexpressed
FGFR3 Watson9 Overexpressed Overexpressed Normal
EGFR Watson9 Overexpressed Overexpressed Normal
PDGFRA Watson9 Overexpressed Overexpressed Overexpressed
NTRK3 Watson9 Overexpressed Overexpressed Normal
KIT Watson9 Normal Overexpressed Overexpressed
NGFR Watson9 Overexpressed Overexpressed Overexpressed
NOTE. For our patient with BCS, the expression status for a gene was classified as overexpressed if its TPM exceeded the gene’s upper 5th
percentile of per-gene RNA-Seq by Expectation-Maximization (RSEM) transcript-per-million (TPM) values for a collection of RNA sequencing
(RNA-Seq) datasets from The Cancer Genome Atlas normal samples. In the study by Watson et al,9 7 tumor transcriptomes from patients with
BCS were analyzed; overexpression was determined as described in the Watson manuscript methods. In the study by Pierron et al,5 10 BCS
tumors were analyzed for certain mRNA expression; overexpression was determined as described in Pierron manuscript methods.
Abbreviations: BCS, BCOR-CCNB3–fused sarcomas; ND, not disclosed.
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10. Riggi N, Suvà ML, Suvà D, et al: EWS-FLI-1 expression triggers a Ewing’s sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res
68:2176-2185, 2008
11. Matsuyama A, Shiba E, Umekita Y, et al: Clinicopathologic diversity of undifferentiated sarcoma with BCOR-CCNB3 fusion: Analysis of 11 cases with
a reappraisal of the utility of immunohistochemistry for BCOR and CCNB3. Am J Surg Pathol 41:1713-1721, 2017
12. Alfaro-Cervello C, Andrade-Gamarra V, Nieto G, et al: Congenital undifferentiated sarcoma associated to BCOR-CCNB3 gene fusion. Pathol Res Pract
213:1435-1439, 2017
13. Judkins AR, Mauger J, Ht A, et al: Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms. Am J Surg Pathol 28:644-650, 2004
14. Modena P, Lualdi E, Facchinetti F, et al: SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res 65:4012-4019,
2005
15. Hornick JL, Dal Cin P, Fletcher CDM: Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol
33:542-550, 2009
16. Sredni ST, Tomita T: Rhabdoid tumor predisposition syndrome. Pediatr Dev Pathol 18:49-58, 2015
17. Chan AK, Han SJ, Choy W, et al: Familial melanoma-astrocytoma syndrome: Synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient
with germline CDKN2A/B deletion and a significant family history. Clin Neuropathol 36:213-221, 2017
18. Campa D, Pastore M, Gentiluomo M, et al: Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect
pancreatic cancer risk. Oncotarget 7:57011-57020, 2016
19. Jouenne F, Chauvot de Beauchene I, Bollaert E, et al: Germline CDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma. J Med Genet
54:607-612, 2017
20. Agarwal SK, Mateo CM, Marx SJ: Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states.
J Clin Endocrinol Metab 94:1826-1834, 2009
21. Knudsen ES, Witkiewicz AK: The strange case of CDK4/6 inhibitors: Mechanisms, resistance, and combination strategies. Trends Cancer 3:39-55, 2017
22. Murakami T, Singh AS, Kiyuna T, et al: Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant
Ewing’s sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget 7:47556-47564, 2016
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